The Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC). This open-access, peer-reviewed journal encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical application. Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for the Journal for ImmunoTherapy of Cancer, an outlet devoted to and created by today's leaders in the field.
SITC welcomes you to read all articles published in JITC at: www.immunotherapyofcancer.org
SITC will be awarding two $1,000 USD awards for papers published in JITC. Awards will be selected by the JITC editorial board and include:
Only original research articles will be considered and eligible manuscripts need to be authored by a SITC member.
SITC Members - don't forget to contact the SITC office to get your SITC Member Code to receive waived article processing charges (a $2,400 USD savings) when you submit your manuscript to JITC.
Less than a year after its first issue, Journal for ImmunoTherapy of Cancer was accepted to PubMed and PubMed Central! This is an exciting step in the evolution of JITC as it now offers greater visibility and accessibility to all articles accepted to JITC – the only journal specifically focused on all aspects of tumor immunology and cancer immunotherapy. Inclusion in PubMed and PubMed Central will make it easier for all scientists, clinicians, patients, educators and students to find, read and cite YOUR articles. All previously published and future articles will be indexed in PubMed and PubMed Central in the near future. Look for future announcements when all articles have been added.
For additional highly accessed articles, click here.
The journal welcomes submissions in the following areas and other related topics:
Basic Tumor Immunology
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions with the anti-tumor immune response, oncolytic viruses
Clinical/Translational Cancer Immunotherapy
First in man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, updates on clinical trials
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies
Triggering discussion on hot topics and innovative concepts
As a way to say thank you to the dedicated Society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, SITC is pleased to offer Society members waived article processing charges for manuscripts accepted before the end of 2014. To take advantage of this member benefit, please call (+414-271-2456) or email (email@example.com) the SITC executive office for your member code.
The Editorial Board is comprised of internationally recognized thought leaders in the field and experts in their content areas. They are also members of SITC and deeply committed to advancing the knowledge about, and integration of, cancer immunotherapy research into the clinical setting.
To see a full listing of the JITC Editorial Board, please click here.